Technical Analysis for IBRX - ImmunityBio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -1.29% | |
| Down 3 Days in a Row | Weakness | -1.29% | |
| MACD Bearish Signal Line Cross | Bearish | -5.56% | |
| Wide Bands | Range Expansion | -5.56% | |
| Shooting Star Candlestick | Bearish | -8.93% | |
| Wide Bands | Range Expansion | -8.93% |
| Alert | Time |
|---|---|
| Up 3% | 1 day ago |
| Up 2% | 1 day ago |
| Up 1% | 1 day ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Fell Below 20 DMA | 2 days ago |
Get a Trading Assistant
- Earnings date: 06/11/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.53 |
| 52 Week Low | 1.25 |
| Average Volume | 7,969,070 |
| 200-Day Moving Average | 3.89 |
| 50-Day Moving Average | 6.32 |
| 20-Day Moving Average | 7.60 |
| 10-Day Moving Average | 8.07 |
| Average True Range | 0.89 |
| RSI (14) | 53.05 |
| ADX | 33.45 |
| +DI | 29.34 |
| -DI | 16.70 |
| Chandelier Exit (Long, 3 ATRs) | 7.87 |
| Chandelier Exit (Short, 3 ATRs) | 7.45 |
| Upper Bollinger Bands | 10.28 |
| Lower Bollinger Band | 4.93 |
| Percent B (%b) | 0.51 |
| BandWidth | 70.40 |
| MACD Line | 0.57 |
| MACD Signal Line | 0.68 |
| MACD Histogram | -0.1081 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.44 | ||||
| Resistance 3 (R3) | 8.49 | 8.28 | 8.31 | ||
| Resistance 2 (R2) | 8.28 | 8.08 | 8.26 | 8.27 | |
| Resistance 1 (R1) | 7.97 | 7.95 | 7.86 | 7.91 | 8.22 |
| Pivot Point | 7.75 | 7.75 | 7.70 | 7.73 | 7.75 |
| Support 1 (S1) | 7.44 | 7.55 | 7.33 | 7.39 | 7.08 |
| Support 2 (S2) | 7.22 | 7.43 | 7.20 | 7.03 | |
| Support 3 (S3) | 6.91 | 7.22 | 6.99 | ||
| Support 4 (S4) | 6.86 |
